AstraZeneca's checkpoint inhibitor Imfinzi has become the first immunotherapy to be approved by the FDA for biliary tract cancer (BTC), a rare and aggressive form of cancer with limited tre
The FDA has kicked off a priority review of AstraZeneca's checkpoint inhibitor Imfinzi for biliary tract cancer (BTC), setting up what could be approval for an immunotherapy for the group o
AstraZeneca's checkpoint inhibitor Imfinzi has become the first cancer immunotherapy to improve survival in previously-untreated patients with biliary tract cancer (BTC), a rare and aggress
